Oncolytics Biotech Inc. · NASDAQ:ONCY
Oncolytics Biotech — Investor Presentation (August 2026)
27 slides from Oncolytics Biotech's investor presentation, August 2026
Slide 1: Pelareorep: a transformative dsRNA immunotherapy platform for gastrointestinal tumors
PELAREOREP a transformative dsRNA immunotherapy platform for gastrointestinal tumors August 2026 1
Slide 2: Disclaimer
DISCLAIMER Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and forward-looking information under applicable securities laws (such forward-looking statements and forward-looking info
Slide 3: Mission
MISSION We will leverage our proprietary product candidate, pelareorep (pela), an investigational first-in-class double-stranded RNA immunotherapeutic agent, to establish a platform immunotherapy for the treatment of gastrointestinal (GI) tumors. We believe GI tumors are the largest unmet medical ne
Slide 4: Pelareorep Mechanism of Action
PELAREOREP MECHANISM OF ACTION Pela infection kills some tumor cells by cell lysis and Intravenous pela evades neutralization by Pela selectively infects and replicates in tumor cells The pela-initiated inflammatory response results in initiates an inflammatory response, through associating with mon
Slide 5: Pelareorep Has Been Observed to Replicate in Almost All Evaluated Tumors
PELAREOREP HAS BEEN OBSERVED TO REPLICATE IN ALMOST ALL EVALUATED TUMORS Pela RNA is found in tumor but not stromal cells Pela is found in almost all on-treatment tumor biopsies Indication treated with IV Pela # of biopsied tumors # Pela-positive biopsies Pancreatic ductal 12 12 adenocarcinoma Metas
Slide 6: Safety Profile
SAFETY PROFILE Pela has been >20 Oncolytics-sponsored studies Multiple cancer indications >1,200 patients treated, evaluated in and several externally sponsored (breast, pancreatic, colorectal, including >300 patients studies (NCI, CCTG, etc.) myeloma, brain, etc.) with GI tumors Most common PELA-ad
Slide 7: Market Opportunities
MARKET OPPORTUNITIES Gastrointestinal cancer is the fastest growing cancer in the world in people under 50 years old • ~ 1,900,000 patients globally1 2L Metastatic • ~ $20 billion total addressable market with 4.7% CAGR to 20332 Colorectal Cancer (mCRC) • RAS mutant patient population high unmet med
Slide 8: Pelareorep Development
Pelareorep Development
Slide 9: Clinical POC Across Targeted Indications Guides Strategic Sequencing
CLINICAL POC ACROSS TARGETED INDICATIONS GUIDES STRATEGIC SEQUENCING Targeted indication SOC benchmark* Pela Data Delta OS: 11.2 mo, PFS: 5.7 mo OS: 27 mo, PFS: 16.6 mo 2L mCRC (RAS-mutated) ~ 2-3x ORR: 6-11%1,2, DOR: 4-6 mo3 ORR: 33%, DOR: 19.5 mo10 ORR: 11-24%4-7 ORR: 30% ≥2L SCAC ~ 1.5-3x DOR: 9.
Slide 10: Clinical Development Pipeline
CLINICAL DEVELOPMENT PIPELINE Program Collaborator Combination Phase 1 Phase 2 Registration-Enabling Phase 3 Anticipated Milestone 2L MSS mCRC RAS-mutated chemo + bev Preliminary data expected Not applicable Biomarker-focused study +/- pela Q4 2026 ≥2L SCAC GOBLET cohort 4 Final data expected pela +
Slide 11: Preclinical Development Pipeline
PRECLINICAL DEVELOPMENT PIPELINE Active and planned programs expanding the pelareorep combination franchise across RAS inhibitors, cell therapies, and targeted modalities Pelareorep is the platform-enabling agent. TME conditioning + IV delivery + tumor-agnostic mechanism = combinable across emerging
Slide 12: Colorectal Cancer Program
Colorectal Cancer Program
Slide 13: Efficacy Results in Colorectal Cancer Demonstrated Across Multiple Studies
EFFICACY RESULTS IN COLORECTAL CANCER DEMONSTRATED ACROSS MULTIPLE STUDIES REO 022 study in 2L KRAS-mutant mCRC results more than double historical third-party benchmarks1, 2, 3, 4: • PFS: 16.6 months vs 5.7 months (pelareorep + FOLFIRI + bevacizumab vs. FOLFIRI + bevacizumab) • OS: 27.0 months vs 1
Slide 14: REO 022 Study: 2L KRAS-mutant MSS mCRC
REO 022 STUDY: 2L KRAS-mutant MSS mCRC The combination of pelareorep with SOC has equated to ORR, PFS, and OS that is 2-3X SOC4 Design Phase 1 dose escalation FOLFIRI + anti-VEGF 15 Part B patients; Metastatic or advanced KRAS- Population FOLFIRI mutated colorectal cancer; Refractory to oxaliplatin
Slide 15: REO 022 Spider & Waterfall Plots
REO 022 SPIDER & WATERFALL PLOTS1 15 1. As of April 9, 2026
Slide 16: REO 033: Controlled Phase 2 Study in 2L RAS-mutated MSS mCRC
REO 033: CONTROLLED PHASE 2 STUDY IN 2L RAS-mutated MSS mCRC Hypothesis: N ≈ 60 (30 per arm, 15-20 sites) Pelareorep + bevacizumab + FOLFIRI will Randomized 1:1 improve clinical outcomes in second-line Primary objective: RAS-mutated MSS metastatic colorectal FOLFIRI + bevacizumab (Avastin®) • Object
Slide 17: Anal Cancer Program
Anal Cancer Program
Slide 18: GOBLET Cohort 4 Swimmer Plot - 20 Evaluable Patients
GOBLET COHORT 4 SWIMMER PLOT - 20 EVALUABLE PATIENTS Number of treatment cycles, 1 cycle = 28 days 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 Treatment Duration Long Term Follow Up Complete Response Partial Response Progressive Disease Stable Disease Death Lost to Follow Up Withdrew Consent to St
Slide 19: GOBLET Cohort Data: Pela + Atezo in ≥2L SCAC
GOBLET COHORT 4 DATA: PELA + ATEZO IN ≥2L SCAC Strong efficacy signal with immunotherapy combination without chemo in difficult cancer 160% PD 140% 128% PD 120% 100% PD Tumor Response % Change From Baseline 100% 79% PD • 30% ORR in 20 evaluable ≥2L patients 80% 60% PD PD PD 60% 50% 45% 41% PD PD PD
Slide 20: Pancreatic Cancer Program
Pancreatic Cancer Program
Slide 21: Consistent Survival Benefit Observed in Multiple 1L mPDAC Studies
CONSISTENT SURVIVAL BENEFIT OBSERVED IN MULTIPLE 1L MPDAC STUDIES 21 mPDAC: metastatic pancreatic ductal adenocarcinoma; DCR: disease control rate; ORR: overall response rate; NCI: National Cancer Institute
Slide 22: 2-Year Survival Rates in 1L Metastatic PDAC: Comparison to Landmark Studies
2-YEAR SURVIVAL RATES IN 1L METASTATIC PDAC: COMPARISON TO LANDMARK STUDIES 2-year Study 2-year Survival Rate survival 0% 10% 20% 30% Pela-based 21.9% REO 017: Pela + G therapy Pela-based 24.0% Comparator NCI 8601: Pela + CP therapy 20.0% Weighted mean = 21.9% treatment 9.2% arms (n=9) Conroy: FOLFI
Slide 23: Regulatory, Intellectual Property and Manufacturing
Regulatory, Intellectual Property and Manufacturing
Slide 24: Regulatory and Commercial Strategy
REGULATORY AND COMMERCIAL STRATEGY Trial Activities Regulatory Strategy Indication Design (estimated) • Clear registrational path in three GI tumors Randomized; • Focus on most efficient regulatory path in high unmet 2L mCRC Sponsored Enrolling patients medical need indications with large commercial
Slide 25: IP Profile and Manufacturing Characteristics
IP PROFILE AND MANUFACTURING CHARACTERISTICS Intellectual Property Manufacturing • Non-genetically modified Reovirus • 139 patents issued worldwide • No special handling requirements • New patent extends manufacturing protection • High yield and low COGs to 2044 and expecting method of use • Made in
Slide 26: Innovative Leadership Team with Strong Immuno-Oncology, Business Development, Clinical Trial and Finance Expertise
INNOVATIVE LEADERSHIP TEAM WITH STRONG IMMUNO-ONCOLOGY, BUSINESS DEVELOPMENT, CLINICAL TRIAL AND FINANCE EXPERTISE Transactional expert Over 20 years of finance Nearly 30 years of drug having led more than 50 and accounting expertise development experience deals, including $2 billion focused on biot
Slide 27: Nasdaq: ONCY
=?) Oncolytics Nasdaq: ONCY
Oncolytics Biotech — Investor Presentation (August 2026) on 6ix